Hemostatic and thrombotic outcomes in patients undergoing therapeutic plasma exchange
Transfusion · 2025
DOI: 10.1111/trf.18320 ↗At a glance
Journal article in Transfusion, 2025. Written by Sirui Ma and 5 co-authors. Institution: Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA. Major MEDLINE topics: Plasma Exchange, Thrombosis, Hemorrhage, Hemostasis. Cited 5 times so far (Crossref); 37 references.
Abstract (original language)
Background
Whether therapeutic plasma exchange (TPE) results in clinically relevant bleeding or thrombotic events is not well characterized. Study Design and Methods We conducted a single‐institution retrospective cohort study to estimate the incidence of bleeding and thrombotic outcomes of patients treated with TPE from 2017 to 2021. Patients with ≥3 treatment sessions within a 14‐day period were included. Two independent physician reviewers manually reviewed patient charts. We calculated the 30‐day cumulative incidence of bleeding and thrombotic outcomes with 95% confidence intervals (CI). We used a regression model to determine the association between clinical and laboratory features and study outcomes.
Results
The study comprised 145 patients who underwent 176 treatment courses, representing a cumulative total of 890 individual TPE procedures. The cumulative incidence of clinically relevant bleeding (including major bleeding and clinically relevant nonmajor bleeding) was 8.0% (95% CI 4.4%–13.0%), and thrombosis was 4.0% (95% CI 1.6%–8.0%). There was one fatal bleeding event. Older age and chronic kidney disease were associated with odds ratios of 1.08 (95% CI 1.03–1.13, p = .002) and 4.68 (95% CI 1.33–14.90, p = .01), respectively, for bleeding. Patients who received any quantity of fresh frozen plasma as replacement fluid had a bleeding rate of 16.4% compared to 6.6% in patients who did not receive plasma ( p = .05).
Discussion
TPE‐associated bleeding complications occur at a higher rate than previously understood. Further prospective investigations are merited to characterize bleeding risk factors and optimal preventive strategies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
- Division of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas, USA.
- Apheresis Services, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
ORCID profiles: Sirui Ma
Cite
APA
Ma, S., Patell, R., Dodge, L., Ma, S., Knox, M., & Carney, B. J. (2025). Hemostatic and thrombotic outcomes in patients undergoing therapeutic plasma exchange. Transfusion. https://doi.org/10.1111/trf.18320
Vancouver
Ma S, Patell R, Dodge L, Ma S, Knox M, Carney BJ. Hemostatic and thrombotic outcomes in patients undergoing therapeutic plasma exchange. Transfusion. 2025. doi:10.1111/trf.18320
BibTeX
@article{Ma2025,
author = {Ma, Sirui and Patell, Rushad and Dodge, Laura and Ma, Shengling and Knox, Michelle and Carney, Brian J},
title = {Hemostatic and thrombotic outcomes in patients undergoing therapeutic plasma exchange},
journal = {Transfusion},
year = {2025},
doi = {10.1111/trf.18320}
}
EUVIMED